Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) was upgraded by Lucid Cap Mkts to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.
A number of other brokerages have also commented on ELOX. Guggenheim assumed coverage on Eloxx Pharmaceuticals in a report on Monday, July 20th. They issued a “buy” rating and a $43.00 price objective on the stock. Wall Street Zen raised Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st. Lifesci Capital assumed coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 target price for the company. Finally, Weiss Ratings initiated coverage on shares of Eloxx Pharmaceuticals in a research report on Friday, August 14th. They issued a “sell (d)” rating for the company. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eloxx Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $41.50.
Get Our Latest Stock Analysis on ELOX
Eloxx Pharmaceuticals Trading Up 16.3%
Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.
Featured Articles
- Five stocks we like better than Eloxx Pharmaceuticals
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
